Research Article
Serum Matrix Metalloproteinase-3 as a Noninvasive Biomarker of Histological Synovitis for Diagnosis of Rheumatoid Arthritis
Table 1
Baseline demographic and clinical features of RA patients.
| | Characteristic | |
| | Demographic | | | Age, yrs, median (IQR) | 56 (48~62) | | Female, (%) | 51 (82) | | Disease status | | | Disease duration, mo, median (IQR) | 30 (12 to 96) | | ESR (mm/h), median (IQR) | 72 (47~107) | | CRP (mg/dL), median (IQR) | 3.9 (1.0~5.6) | | Rheumatoid factor-positive, (%) | 54 (87) | | Anti-CCP-positive, (%) | 50 (81) | | SDAI, median (IQR) | 33 (24~44) | | CDAI, median (IQR) | 29 (20~40) | | DAS28, median (IQR) | 5.5 (4.6~6.3) | | Synovitis score, median (IQR) | 4 (4~6) | | High grade synovitis, (%) | 27 (44) | | Previous medications, (%) | | | Corticosteroids | 26 (42) | | Methotrexate | 20 (32) | | Leflunomide | 6 (10) | | Sulfasalazine | 5 (8) | | Hydroxychloroquine | 7 (11) | | Etanercept | 4 (6) |
|
|
